Iwamaru Arifumi, Iwado Eiji, Kondo Seiji, Newman Robert A, Vera Burnilda, Rodríguez Abimael D, Kondo Yasuko
Department of Neurosurgery, Unit BSRB1004, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Mol Cancer Ther. 2007 Jan;6(1):184-92. doi: 10.1158/1535-7163.MCT-06-0422.
The marine ecosystem is a vast but largely untapped resource for potential naturally based medicines. We tested 15 compounds derived from organisms found in the Caribbean Sea (14 gorgonian octocoral-derived compounds and one sponge-derived compound) for their anticancer effects on human malignant glioma U87-MG and U373-MG cells. Eupalmerin acetate (EPA) was chosen as the lead compound based on its longer-term stability and greater cytotoxicity than those of the other compounds we tested in these cell types. EPA induced G(2)-M cell cycle arrest and apoptosis via the mitochondrial pathway; it translocated Bax from the cytoplasm to the mitochondria and dissipated the mitochondrial transmembrane potential in both cell types. EPA was found to increase phosphorylated c-Jun NH(2)-terminal kinase (JNK) by >50% in both U87-MG and U373-MG cells. A specific JNK inhibitor, SP600125, inhibited EPA-induced apoptosis, confirming the involvement of the JNK pathway in EPA-induced apoptotic cell death. Furthermore, 7 days of daily intratumoral injections of EPA significantly suppressed the growth of s.c. malignant glioma xenografts (P < 0.01, on day 19). These results indicate that EPA is therapeutically effective against malignant glioma cells in vitro and in vivo and that it, or a similar marine-based compound, may hold promise as a clinical anticancer agent.
海洋生态系统是一个巨大但在很大程度上尚未开发的潜在天然药物资源。我们测试了15种从加勒比海生物中提取的化合物(14种柳珊瑚八放珊瑚衍生化合物和1种海绵衍生化合物)对人类恶性胶质瘤U87-MG和U373-MG细胞的抗癌作用。基于乙酸优帕美灵(EPA)在这些细胞类型中比我们测试的其他化合物具有更长的稳定性和更大的细胞毒性,我们选择它作为先导化合物。EPA通过线粒体途径诱导G(2)-M期细胞周期阻滞和凋亡;它使Bax从细胞质转移到线粒体,并使两种细胞类型的线粒体跨膜电位消散。我们发现EPA在U87-MG和U373-MG细胞中均使磷酸化的c-Jun氨基末端激酶(JNK)增加超过50%。一种特异性JNK抑制剂SP600125抑制了EPA诱导的凋亡,证实JNK途径参与了EPA诱导的凋亡性细胞死亡。此外,每天瘤内注射EPA 7天显著抑制了皮下恶性胶质瘤异种移植瘤的生长(第19天,P < 0.01)。这些结果表明,EPA在体外和体内对恶性胶质瘤细胞具有治疗效果,并且它或类似的海洋基化合物可能有望成为临床抗癌药物。